---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-041514"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T21:50:40.319715+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Vanda approves 2023 bonuses, 2024 salaries, and RSU grants for NEOs

## Summary
- CEO Polymeropoulos receives $983K bonus for 2023, 450,000 RSUs vesting over 4 years.
- 2024 base salaries: CEO $933K, CFO Moran $541K, others $541-560K.
- 2024 target bonuses: 80% CEO, 45% for other NEOs.
- RSU grants total 857,700 shares across five executives.
- Compensation committee reviewed Willis Towers Watson peer group analysis.

## SEC filing metadata
- accession: 0001193125-24-041514
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000119312524041514/0001193125-24-041514-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000119312524041514/d796267d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-041514
- JSON: https://secwatch.observer/filing/0001193125-24-041514.json
- Plain text: https://secwatch.observer/filing/0001193125-24-041514.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.